Does ANTISENSE THERAPEUTICS LTD ORDINARY SHAR (OTCMKTS:ATHJF) Have Gas After Even More Sellers Involved?

November 10, 2018 - By Ruchi Gupta

The stock of ANTISENSE THERAPEUTICS LTD ORDINARY SHAR (OTCMKTS:ATHJF) registered an increase of 1500% in short interest. ATHJF’s total short interest was 1,600 shares in November as published by FINRA. Its up 1500% from 100 shares, reported previously. With 300 shares average volume, it will take short sellers 5 days to cover their ATHJF’s short positions.

It closed at $0.035 lastly. It is down 0.00% since November 10, 2017 and is . It has underperformed by 15.62% the S&P500.

Antisense Therapeutics Limited engages in the research and development of antisense pharmaceuticals in Australia. The company has market cap of $8.95 million. The company's product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of insulin like growth factor 1 receptor for prostate cancer treatment. It currently has negative earnings. The Company’s product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as a potential treatment for diseases associated with excessive growth hormone action.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>